ForGrace

ForGrace is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics for immune-mediated inflammatory diseases. The company's research is primarily centered on the Th17/IL-17 axis, a critical pathway in the pathogenesis of various autoimmune conditions. Its lead candidate, FGR-101, is a potent and selective RORγt inverse agonist currently in Phase 2 clinical trials for the treatment of plaque psoriasis. ForGrace is also advancing FGR-202, a TYK2 inhibitor, alongside other early-stage programs targeting dermatology and gastroenterology indications. By focusing on oral small molecules, the company aims to provide patients with more convenient and accessible alternatives to traditional injectable biologic therapies. The firm leverages its internal R&D capabilities and strategic partnerships to accelerate the delivery of next-generation immunology treatments.